arrow
N

Nicola Colclough

dmpk
H指数:24
被引数:3,013

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions

AZ14289671 是一种高选择性的血脑屏障穿透性不可逆TKI,可靶向EGFRExon20插入突变。

2025-08-250
OAAI
Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase

通过口服A-T突变酶抑制剂AZD1390(醛氧化酶底物)实现人脑暴露。

2025-06-030
PRE
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
2024-09-280
PRE
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations
2024-05-212
PRE
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390
2024-02-024
PRE
Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
2022-12-1216
OAAI
Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development

未结合的脑-血浆分配系数,Kp,uu,脑-CNS药物发现和开发的游戏改变参数

2022-04-1162
OAAI
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
2021-09-0721
PRE
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs

奥希替尼与其他EGFR tki的血脑屏障通透性的临床前比较

2021-01-04130
OAAI
Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)
2019-07-011
PRE
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2018-07-3154
OAAI
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors
2018-07-1326
OAAI
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
2018-06-01221
OAAI
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
2018-04-23101
OAAI
AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models
2018-01-013
PRE